GLUE

Monte Rosa Therapeutics, Inc. Common Stock

10.57

USD

+0.32

+3.12%

Nov 06, 15:59 UTC -5

Closed

After-Market

10.56

-0.01

-0.05%

Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Earnings

GLUE Earnings Reports

Positive Surprise Ratio

GLUE beat 15 of 22 last estimates.

68%

Next Report

Date of Next Report

Mar 15, 2027

Estimate for Q4 26 (Revenue/ EPS)

$11.43M

-$0.47

Implied change from Q3 26 (Revenue/ EPS)

-78.97%

-1666.67%

Implied change from Q4 25 (Revenue/ EPS)

+311.11%

-16.07%

Monte Rosa Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, GLUE reported earnings of 0.03 USD per share (EPS) for Q3 26, beating the estimate of -0.29 USD, resulting in a 110.09% surprise. Revenue reached 54.37 million, compared to an expected 30.34 million, with a 79.17% difference. The market reacted with a -5.27% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.47 USD, with revenue projected to reach 11.43 million USD, implying an decrease of -1666.67% EPS, and decrease of -78.97% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

INmune Bio Inc. Common stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.14

Actual

-$0.17

Surprise

-13.64%

FAQ

What were Monte Rosa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Monte Rosa Therapeutics, Inc. Common Stock reported EPS of $0.03, beating estimates by 110.09%, and revenue of $54.37M, 79.17% above expectations.

How did the market react to Monte Rosa Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -5.27%, changed from $10.82 before the earnings release to $10.25 the day after.

When is Monte Rosa Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 15, 2027.

What are the forecasts for Monte Rosa Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Monte Rosa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.47 and revenue of $11.43M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.